Semaglutide research peptide is supplied to qualified Canadian institutions as a characterized laboratory material for in vitro GLP-1 receptor signalling studies. The compound is a GLP-1 analogue modified with α-aminoisobutyric acid at position 8 and a C18 diacid spacer (NN9535).

In vitro, the position-8 substitution resists DPP-4 cleavage and the diacid supports albumin binding, which is why the analogue is used as a reference agonist in GLP-1 receptor signalling and biased-agonism assays. Typical designs record receptor occupancy or second-messenger readouts in GLP-1-receptor-expressing cells. This listing describes receptor pharmacology in experimental systems only.

The material is offered as a lyophilized vial. Identity data (CAS 910463-68-2, formula C187H291N45O59, molecular weight 4113.6 g/mol, PubChem CID 56843331) are listed on the specification table. Store lyophilized at −20 °C, protected from light, and handle under the receiving institution's chemical-hygiene plan.

Lots are sourced from a GMP-aligned peptide manufacturing partner and released against the stated HPLC purity for that lot (≥99% by HPLC, lot-specific). Identity, chromatographic purity, and related analytical results are documented on the lot certificate of analysis (COA). Retain the COA with the inventory record.

This listing is a research-use-only peptide offered to qualified Canadian institutions for in vitro and laboratory use. Purchasing access is limited to verified Canadian research institutions; individual consumer accounts are not accepted. It is not for human or veterinary use, is not intended for diagnostic procedures, and has not been evaluated or authorized by Health Canada as a drug, diagnostic, or medical product.